Aquapass’s fluid overload therapy system gains marketing approval in Israel
December 9, 2025
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
In a new leap for neurobiology and bioelectronics, Northwestern University scientists have developed a wireless device that uses light to send information directly to the brain—bypassing the body’s natural sensory pathways.
NES ZIONA, Israel, Dec. 8, 2025 /PRNewswire/ — EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world’s first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.
15-minute test developed at Northwestern provides results up to 75% faster than current rapid tests
Using a versatile problem-solving framework, researchers show how early relapse in lymphoma patients influences their chance for survival.
SS Innovations (Nasdaq:SSII) announced today that it submitted a 510(k) premarket notification to the FDA for its Mantra surgical robot.
Resmed (NYSE: RMD)+
announced today that it received FDA clearance for its Smart Comfort personalized therapy offering.
Healthcare professionals can access the 1Bio AI-Acute toolbox via the company’s 1Bio platform.
Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services. That’s what happens inside cells when the 3D structure of DNA collapses.
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer.